Premium
Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and A po B in patients undergoing primary prevention of cardiovascular disease: A triple‐blind, 6‐month follow‐up, placebo‐controlled, randomized trial
Author(s) -
ToméCarneiro Joao,
Gonzálvez Manuel,
Larrosa Mar,
GarcíaAlmagro Francisco J.,
AvilésPlaza Francisco,
Parra Soledad,
YáñezGascón María J.,
RuizRos José A.,
GarcíaConesa María T.,
TomásBarberán Francisco A.,
Espín Juan Carlos
Publication year - 2012
Publication title -
molecular nutrition and food research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.495
H-Index - 131
eISSN - 1613-4133
pISSN - 1613-4125
DOI - 10.1002/mnfr.201100673
Subject(s) - resveratrol , apolipoprotein b , placebo , statin , atorvastatin , grape seed extract , medicine , cholesterol , endocrinology , chemistry , pharmacology , alternative medicine , pathology
Scope The cardioprotective role of resveratrol as part of the human diet is not yet clear. Our aim was to investigate the effect of a grape supplement containing 8 mg resveratrol in oxidized LDL ( LDL ox), apolipoprotein‐ B ( A po B ), and serum lipids on statin‐treated patients in primary cardiovascular disease prevention ( PCP ). Methods and results A triple‐blind, randomized, placebo‐controlled trial was conducted. Seventy‐five patients (three parallel arms) consumed one capsule (350 mg) daily for 6 months containing resveratrol‐enriched grape extract ( GE ‐ RES , S tilvid®), grape extract ( GE , similar polyphenolic content but no resveratrol), or placebo (maltodextrin). After 6 months, no changes were observed in the placebo group and only LDL cholesterol ( LDL c) decreased by 2.9% ( p = 0.013) in the GE group. In contrast, LDL c (−4.5%, p = 0.04), A po B (−9.8%, p = 0.014), LDL ox (−20%, p = 0.001), and LDL ox/ A po B (−12.5%, p = 0.000) decreased in the S tilvid® group, whereas the ratio non‐ HDL c (total atherogenic cholesterol load)/ A po B increased (8.5%, p = 0.046). No changes were observed in hepatic, thyroid, and renal function. No adverse effects were observed in any of the patients. Conclusion This GE ‐ RES reduced atherogenic markers and might exert additional cardioprotection beyond the gold‐standard medication in patients from PCP . The presence of resveratrol in the GE was necessary to achieve these effects.